{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:08:45Z","timestamp":1785614925271,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.schres.2013.05.023","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T18:32:12Z","timestamp":1371148332000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy"],"prefix":"10.1016","volume":"148","author":[{"given":"Stephen I.","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina R.","family":"Schooler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Rosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Rosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2013.05.023_bb0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-3565(24)36503-6","article-title":"Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function","volume":"280","author":"Albuquerque","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2013.05.023_bb0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0928-4257(98)80039-9","article-title":"Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of \u03b17 receptors","volume":"92","author":"Albuquerque","year":"1998","journal-title":"J. Physiol. Paris"},{"key":"10.1016\/j.schres.2013.05.023_bb0015","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1111\/j.1460-9568.1997.tb01702.x","article-title":"Choline is a selective agonist of \u03b17 nicotinic acetylcholine receptors in the rat brain neurons","volume":"9","author":"Alkondon","year":"1997","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.schres.2013.05.023_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/13854048908403285","article-title":"Predicting premorbid IQ: a revision of the National Adult Reading Test","volume":"3","author":"Blair","year":"1989","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.schres.2013.05.023_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.49.3.671","article-title":"A randomized dose-response trial of citicoline in acute ischemic stroke patients","volume":"49","author":"Clark","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.schres.2013.05.023_bb0030","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1161\/01.STR.30.12.2592","article-title":"A randomized efficacy trial of citicoline in patients with acute ischemic stroke","volume":"30","author":"Clark","year":"1999","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.schres.2013.05.023_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/WNF.0b013e31816f2795","article-title":"The effects of galantamine on psychopathology in chronic stable schizophrenia","volume":"32","author":"Conley","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2013.05.023_bb0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1046\/j.1471-4159.1999.0731590.x","article-title":"Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: \u03b1-bingarotoxin and nicotine binding in thalamus","volume":"73","author":"Court","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2013.05.023_bb0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2013.05.023_bb0050","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.STR.0000038691.03334.71","article-title":"Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials","volume":"33","author":"Davalos","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.schres.2013.05.023_bb0055","first-page":"33","article-title":"Therapeutic implications of a selective \u03b17 nicotinic receptor abnormality in schizophrenia","volume":"42","author":"Deutsch","year":"2005","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"issue":"1","key":"10.1016\/j.schres.2013.05.023_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/wnf.0b013e31806462ba","article-title":"First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy","volume":"31","author":"Deutsch","year":"2008","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.schres.2013.05.023_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1037\/a0014699","article-title":"Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis","volume":"14","author":"Feingold","year":"2009","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.schres.2013.05.023_bb0070","first-page":"CD000269","article-title":"Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly","volume":"4","author":"Fioravanti","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.05.023_bb0075","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV)","author":"First","year":"1996"},{"key":"10.1016\/j.schres.2013.05.023_bb0080","series-title":"Applied Longitudinal Analysis","first-page":"128","author":"Fitzmaurice","year":"2011"},{"key":"10.1016\/j.schres.2013.05.023_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.94.2.587","article-title":"Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus","volume":"94","author":"Freedman","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.schres.2013.05.023_bb0095","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-004-1846-2","article-title":"Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects","volume":"174","author":"Geyer","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2013.05.023_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2013.05.023_bb0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuropharm.2010.07.007","article-title":"Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential","volume":"60","author":"Gregory","year":"2011","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.schres.2013.05.023_bb0115","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/00001756-199906030-00028","article-title":"Decreased protein level of nicotinic receptor [alpha]7 subunit in the frontal cortex from schizophrenic brain","volume":"10","author":"Guan","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.schres.2013.05.023_bb0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hipo.1068","article-title":"Neuroimaging studies of the hippocampus in schizophrenia","volume":"11","author":"Heckers","year":"2001","journal-title":"Hippocampus"},{"key":"10.1016\/j.schres.2013.05.023_bb0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/1137","article-title":"Impaired recruitment of the hippocampus during conscious recollection in schizophrenia","volume":"1","author":"Heckers","year":"1998","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2013.05.023_bb0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0896-6273(01)00332-4","article-title":"Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity","volume":"231","author":"Ji","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2013.05.023_bb0135","first-page":"1","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","author":"Jones","year":"2011","journal-title":"Neuropsychopharmacol. Rev."},{"issue":"Suppl 7","key":"10.1016\/j.schres.2013.05.023_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","volume":"155","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0145","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene are associated with an inhibitory deficit found in schizophrenia","volume":"59","author":"Leonard","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0150","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"8","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2013.05.023_bb0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0079-6468(07)00003-3","article-title":"\u03b17 nicotinic acetylcholine receptor agonists and positive allosteric modulators","volume":"46","author":"Lightfoot","year":"2008","journal-title":"Prog. Med. Chem."},{"issue":"12","key":"10.1016\/j.schres.2013.05.023_bb0160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(06)78008-4","article-title":"Schizophrenia and the \u03b17 nicotinic acetylcholine receptor","volume":"78","author":"Martin","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2013.05.023_bb0170","series-title":"Manual for the ECDEU Assessment Battery","article-title":"CGI: Clinical Global Impressions","author":"National Institute of Mental Health","year":"1970"},{"issue":"2","key":"10.1016\/j.schres.2013.05.023_bb0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0180","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an \u03b17 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2013.05.023_bb0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/13803390490510130","article-title":"Aging, recall, and recognition: a study on the sensitivity of the University of Southern California Repeatable Episodic Memory Test (USC-REMT)","volume":"26","author":"Parker","year":"2004","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"8","key":"10.1016\/j.schres.2013.05.023_bb0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1176\/appi.ajp.2009.08091307","article-title":"Prefrontal activation deficits during episodic memory in schizophrenia","volume":"166","author":"Ragland","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2013.05.023_bb0195","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00019442-199622430-00005","article-title":"Validation of the scale of functioning in older outpatients with schizophrenia","volume":"4","author":"Rapaport","year":"1996","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.schres.2013.05.023_bb0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2005.01.030","article-title":"Presynaptic \u03b17 and non-\u03b17 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro","volume":"49","author":"Rousseau","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2013.05.023_bb0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2008.04.005","article-title":"Recognition memory probes affect what is remembered in schizophrenia","volume":"167","author":"Schwartz","year":"2009","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.schres.2013.05.023_bb0210","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0006-2952(00)00436-6","article-title":"Effect of oral CDP-choline on plasma choline and uridine levels in humans","volume":"60","author":"Wurtman","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.schres.2013.05.023_bb0215","series-title":"Citicoline: Efficacy & Safety Review: Clinical Expert Report. Submission to the Regulatory Authorities of Belgium and Portugal for the European Economic Community","author":"Wurtman","year":"2001"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T12:12:00Z","timestamp":1746015120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":43,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0920996413002788"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.05.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}